Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1097)	11/14/2002 1:14:32 PM
From: DEER HUNTER	Respond to of 1906

Dow Jones Business News Wyeth CFO: No Need To Rush To Sell Amgen Stake Thursday November 14, 12:11 pm ET By Hollister H. Hovey, Of DOW JONES NEWSWIRES biz.yahoo.com Another source of cash for Wyeth will be the sale of its stake in Amgen Inc. (NasdaqNM:AMGN - News) , but Martin said the company is in no hurry to drop the shares, though it intends to eventually. Wyeth, which owns almost 98.3 million shares, or 7.7% of Amgen's common stock, was a big holder in Immunex Corp. before Amgen closed its acquisition of the company on July 15. Wyeth cannot sell more than 20 million Amgen shares a quarter, according to the agreement, the Aug. 8 filing said. "We like Amgen," Martin said. "We like them as a partner for marketing Enbrel. So we like them from that standpoint. We like the future prospects of the company. There's no need to rush to sell this position."